Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATN-161 in Advanced Renal Cell Cancer
NCT00131651Phase 2Terminated
- Sponsor
- Attenuon LLC
- Start
- Aug 2005
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ATN161 in clear cell renal cell carcinoma (ccRCC) (3 arms), sponsored by Attenuon LLC. Primary endpoint: Reduction in tumor blood flow and permeability of vessels at Week 4. Started Aug 2005; status: terminated.
02
Drugs
ATN161
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT00131651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00131651.